Healthcare / BiotechnologyASX
$0.07
+0.00 (+1.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-7.0M · quality 35.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$87M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-37.4%
↓Gross Margin
100.0%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-22.8%
FCF CAGR
—
FCF margin
-5399.2%
FCF / Net income
0.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $136000.0 · net income $-7.5M · FCF $-7.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $136000.00 | $136000.00 | $17000.00 | $405898.00 | $295810.00 |
| Net Income | $-7.5M | $-7.5M | $-8.7M | $-10.2M | $-8.6M |
| EBITDA | $-11.1M | $-11.1M | $-8.7M | $-9.3M | $-7.9M |
| EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 49.9% | 30.0% |
| Operating Margin | -8237.3% | -8237.3% | -63595.7% | -2385.0% | -2568.0% |
| Net Margin | -5521.4% | -5521.4% | -51447.3% | -2508.4% | -2914.2% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | — | 0.02 |
| Current Ratio | 15.36 | 15.36 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.3M | $-7.3M | $-7.0M | $-6.4M | $-6.8M |
| Returns | |||||
| ROE | -37.4% | -37.4% | -77.9% | -269.3% | -113.2% |
| Valuation | |||||
| P/B | 3.93 | 3.93 | 12.58 | 9.41 | 1.88 |
| Growth & Yield | |||||
| Revenue Growth | 700.0% | 700.0% | -95.8% | 37.2% | — |
| EPS Growth | 26.9% | 26.9% | 35.0% | 8.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.01
Residual
-7.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.